How can we prevent cardiovascular disease in diabetes

Authors

  • O. Wiklund,

    1. From the Department for Molecular and Clinical Medicine and the Wallenberg Laboratory, Sahlgrenska Academy at Göteborg University, Göteborg, Sweden
    Search for more papers by this author
  • L. Håversen,

    1. From the Department for Molecular and Clinical Medicine and the Wallenberg Laboratory, Sahlgrenska Academy at Göteborg University, Göteborg, Sweden
    Search for more papers by this author
  • C. Pettersson,

    1. From the Department for Molecular and Clinical Medicine and the Wallenberg Laboratory, Sahlgrenska Academy at Göteborg University, Göteborg, Sweden
    Search for more papers by this author
  • L. M. Hultén

    1. From the Department for Molecular and Clinical Medicine and the Wallenberg Laboratory, Sahlgrenska Academy at Göteborg University, Göteborg, Sweden
    Search for more papers by this author

Olov Wiklund MD, PhD, Wallenberg Laboratory, Sahlgrenska University Hospital, 413 45 Göteborg, Sweden.
(fax: +46 31 823762; e-mail: olov.wiklund@wlab.gu.se).

Abstract.

Evidence based goals for the treatment and prevention of atherosclerosis in diabetes are given in international and national guidelines. The importance of optimal control of lipids and blood pressure has been shown in several studies. With available drugs and behavioural modifications the treatment goals can be reached in most cases. However, only a few patients with diabetes are treated optimally today. A major possibility to reduce cardiovascular disease in diabetes is to treat patients according to guidelines.

New treatment targets may include specific treatment of the dyslipidaemia, manifested in high levels of small dense LDL and low HDL, active anti-inflammatory treatments, specific reduction of inflammatory activity in adipose tissue, reduced volume of adipose tissue, antioxidants and reduction of advanced glycosylation endproducts production. Possible strategies for these treatments are available, and should be evaluated in clinical trials.

Ancillary